To determine the average fasting, postprandial, and bedtime self-monitored blood glucose (SMBG) concentrations associated with specified HbA 1c levels using data from the A1c-Derived Average Glucose (ADAG) study.
Recent diabetes management guidelines specify that treatment goals should be individualized based on age, comorbidities, and duration of disease, with an American Diabetes Association (ADA)/European Association for the Study of Diabetes goal of ,7% (,53 mmol/mol) or American Association of Clinical Endocrinologists (AACE) goal of #6.5% (#48 mmol/mol) in otherwise healthy patients (1,2). Although HbA 1c is the target, it is measured once every 3 months, and day-to-day selfmanagement of diabetes to achieve and maintain the individualized target HbA 1c is facilitated by self-monitored blood glucose (SMBG) values, especially in patients treated with insulin (1-4). To achieve the recommended HbA 1c goals, the ADA, the European Association for the Study of Diabetes, the AACE, and the International Diabetes Federation (IDF) have recommend SMBG targets (Table 1) , the origins of which are obscure but appear to be based predominantly on expert opinion (1-5). As a result, there is wide variation in the recommended SMBG targets to achieve a HbA 1c ,7% (,53 mmol/mol) and little to guide clinicians and patients on how to achieve other, individualized, targets.
We sought to determine the average fasting, postprandial, and bedtime glucose values, based on empirical data, to achieve and maintain target HbA 1c levels in the outpatient setting.
RESEARCH DESIGN AND METHODS
We analyzed blood glucose (BG) data from the A1c-Derived Average Glucose (ADAG) study, which was conducted to establish the relationship between average glucose concentrations and HbA 1c levels (6) We performed the current analyses on 378 of the originally published cohort (237 type 1 diabetes patients, representing 88% of the original ADAG study cohort, and 141 type 2 diabetes patients, 89% of original cohort). They were selected based on having HbA 1c values at 3 months between 5.5 and 8.5% (37-69 mmol/mol). These subjects had a total of 30,108 HemoCue BG values (4,031 fasting, 12,943 before meal, 12,602 90 min after a meal, and 4,563 at bedtime) monitored over an average of 11 days per participant during the 12-week study period. There were, on average, 9 fasting, 28 premeal (including fasting), 27 postmeal, and 7 bedtime HemoCue (SMBG) values for each subject.
We calculated the mean fasting, premeal, postmeal, and bedtime BG for each participant. For each HbA 1c group of 5.5-6.49% (37-47 mmol/mol), 6.5-6.99% (48-52 mmol/mol), 7.0-7.49% (52-58 mmol/mol), 7.5-7.99% (58-64 mmol/mol), and 8.0-8.5% (64-69 mmol/mol), the mean fasting, premeal, postmeal, and bedtime BG of the participants within the group were averaged. The mean premeal, postmeal, and bedtime BG were compared between type 1 and type 2 diabetes patients using t tests.
All analyses were performed with SAS version 9.3. The protocol was approved by the Partners Healthcare Institutional Review Board.
RESULTS
Mean fasting, premeal, 90-min postmeal, and bedtime BG in each HbA 1c group of 5.5-6.49% (37-47 mmol/mol), 6.5-6.99% (48-52 mmol/mol), 7.0-7.49% (52-58 mmol/mol), 7.5-7.99% (58-64 mmol/mol), and 8.0-8.5% (64-69 mmol/mol) are summarized in There were significant differences in mean premeal and postmeal BG between specified breakfast, lunch, and supper meals, with the average The consequences of using the previously published, nonempirical data may include pushing patients harder to achieve lower fasting levels than are actually required. Considering the safety concerns surrounding hypoglycemia, in particular, nocturnal hypoglycemia and hypoglycemia unawareness, the current recommended glucose targets emphasizing lower fasting BG and higher postprandial BG should be reevaluated. The target BG levels necessary to achieve specified HbA 1c values were generally similar for type 1 and type 2 diabetes patients ( The choice of glucose monitoring schedule and goals remains complex, predicated on target HbA 1c , treatment regimens, risk of hypoglycemia, and cost-effectiveness. For patients and providers, setting appropriate day-to-day BG testing goals to achieve a specific and individualized HbA 1c target is important to guide the patient's selfcare and self-management. The current study establishes realistic target BG levels, based on empirical data, to inform our patient-centered care. We hope that these data will be used by professional societies, clinicians, and patients to guide the appropriate choice of glucose targets and treatment to achieve their individualized HbA 1c goal.
